Telix Pharmaceuticals’ (TLX) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research report sent to investors on Monday,Benzinga reports. Wedbush currently has a $22.00 price objective on the stock.

A number of other analysts have also recently commented on TLX. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Price Performance

Shares of TLX stock opened at $11.83 on Monday. The firm’s fifty day moving average price is $11.25 and its two-hundred day moving average price is $10.27. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $13.11.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its position in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares during the period. XY Capital Ltd bought a new stake in shares of Telix Pharmaceuticals in the first quarter valued at about $120,000. Lazard Asset Management LLC boosted its position in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after acquiring an additional 39,400 shares during the period. Private Advisor Group LLC grew its stake in shares of Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after acquiring an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at about $1,731,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.